南京诺唯赞生物科技股份有限公司 2025 年第三季度报告 证券代码：688105 证券简称：诺唯赞 南京诺唯赞生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 | | | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 346,183,744.66 | 2.84 | 952,404,074.47 | -3.40 | | 利润总额 | -6,902,600.10 | 不适 ...

南京诺唯赞生物科技股份有限公司 关联交易管理制度 第一章 总 则 第一条 为规范南京诺唯赞生物科技股份有限公司（以下简称"公司"）与 关联人之间发生的关联交易，提高公司规范运作水平，保护公司和全体股东的合 法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券 交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 5 号— 交易与关联交易》等法律、法规、规范性文件和《南京诺唯赞生物科技股份有限 公司章程》（以下简称"《公司章程》"），制定本制度。 第二条 公司的关联交易应当遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）不损害公司及非关联股东合法权益的原则； （四）关联股东及董事回避的原则。 第三条 公司的关联交易应当定价公允、决策程序合规、信息披露规范，保 证关联交易的合法性、必要性、合理性和公允性，保持公司的独立性，不得利用 关联交易调节财务指标，损害公司利益。 第二章 关联人 第四条 公司的关联人，指具有下列情形之一的自然人、法人或其他组织： （一）直接或者间接控制公司的自然人、法人或其他组织； （二）直接或间接持有公司 5%以 ...

南京诺唯赞生物科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第二章 人员组成 1 提名委员会可以现场方式召开，也可以视频、电话、传真或者电子邮件表 决等非现场方式召开。 提名委员会会议由召集人负责召集和主持，召集人不能出席时可委托其他 委员主持。召集人既不能履行职责，也不委托其他委员代行其职责时，半 数以上委员可选举出 1 名委员代行召集人职责，并将有关情况及时向公司 董事会报告。 第一条 南京诺唯赞生物科技股份有限公司(以下简称"公司")为规范董事及高级 管理人员的产生，优化董事会组成，完善公司治理结构，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号—规范运作》《南京诺唯赞生物科技股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，公司董事会设立提名委员会， 并制定本议事规则。 第二条 董事会提名委员会是董事会按照《公司章程》设立的专门工作机构，主要 负责研究并制定董事、总经理人员的选择标准和选择程序，同时对董事长 提名的董事会秘书、总经理提名的其他高级管理人员人选 ...

第二章 会计师事务所执业质量要求 第五条 公司选聘的会计师事务所应当满足以下条件： 南京诺唯赞生物科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范南京诺唯赞生物科技股份有限公司（以下简称"公司"）选 聘（含续聘、改聘，下同）会计师事务所的行为，切实维护股东利益，提高审计 工作和财务信息的质量，根据《中华人民共和国公司法》《国有企业、上市公司 选聘会计师事务所管理办法》《上海证券交易所科创板股票上市规则》等法律法 规、规范性文件以及《南京诺唯赞生物科技股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可比照本 制度执行。 第三条 公司选聘或解聘会计师事务所，应当经董事会审计委员会（以下简 称"审计委员会"）审议同意后，提交董事会审议，并由股东会审议决定。公司 不得在股东会审议前聘请会计师事务所开展审计业务。 第四条 公司控股股东、实际控制人不得向公司指 ...

Core Points - The stock price of NuoVasive increased by 2.05% on October 27, reaching 22.92 CNY per share, with a total market capitalization of 9.116 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.09%, with a 4.37% rise over the last five trading days [1] Company Overview - NuoVasive, established on March 16, 2012, and listed on November 15, 2021, is a biotechnology company based in Nanjing, Jiangsu Province, focusing on the research and development of functional proteins and high molecular organic materials [1] - The company's main business revenue composition includes: 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [1] Financial Performance - For the first half of 2025, NuoVasive reported a revenue of 606 million CNY, a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.1294 million CNY, down 80.63% year-on-year [2] - The company has distributed a total of 731 million CNY in dividends since its A-share listing, with 611 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders for NuoVasive was 8,596, an increase of 2.37% from the previous period, with an average of 46,269 circulating shares per shareholder, a decrease of 2.31% [2]

Core Insights - The collagen market is experiencing significant growth driven by increasing consumer focus on efficacy and ingredients, with two main growth drivers: professional skin care and aesthetic injection applications [1][3] - The collagen market in China is projected to exceed 16 billion yuan at the raw material level and approach 270 billion yuan at the retail level by 2030 [1] - The industry is currently in a phase of policy refinement, accelerated technological iteration, and tight collaboration across the supply chain [1] Industry Structure - The collagen industry has a high degree of integration between raw material supply and end product manufacturing, with upstream suppliers, midstream manufacturers of recombinant collagen, and downstream sales channels [2] - The market is characterized by significant growth potential, high technological barriers, and intense competition [2] End-User Applications - The demand for professional skin care products that combine medical safety and cosmetic efficacy is rapidly increasing, particularly in the aesthetic medicine sector [3] - Applications of collagen products are expanding from traditional moisturizing and nourishing functions to include core roles in aesthetic injection materials [3] Recommended Companies - Companies to watch include: Giant Bio (02367), Jinbo Bio (920982.BJ), Marubi Bio (603983.SH), Huaxi Bio (688363.SH), Fulejia (301371.SZ), Novozymes (688105.SH), Baipusais (301080.SZ), and Betaini (300957.SZ) [4]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.14% on October 20, with Iwu Biologics leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Biopharmaceutical Sector Performance - Iwu Biologics (300357) saw a significant rise of 10.07%, closing at 32.90 with a trading volume of 228,200 shares and a transaction value of 737 million [1] - Other notable gainers included Olin Biologics (6168889) with a 4.58% increase, closing at 23.96, and Kangchen Pharmaceutical (603590) with a 4.00% increase, closing at 51.19 [1] - The sector also had some underperformers, such as Novavax (688105) which fell by 3.56%, closing at 21.96 [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 239 million from institutional investors, while retail investors saw a net inflow of 270 million [2] - The data indicates that retail investors are actively buying into the sector despite the overall net outflow from larger institutional players [2] Individual Stock Capital Flow - Iwu Biologics had a net inflow of 23.19 million from institutional investors, while it faced a net outflow of 17.27 million from speculative funds [3] - Notably, Huashan Biologics (002007) had a net inflow of 42.16 million from institutional investors, indicating strong institutional interest [3]

Core Viewpoint - The stock of NuoVasive (688105.SH) closed at 21.96 yuan, reflecting a decline of 3.56% and currently in a state of breaking issue [1] Group 1: Company Overview - NuoVasive was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2021, with an issuance of 40.01 million shares at a price of 55.00 yuan per share [1] - The total funds raised from the initial public offering (IPO) amounted to 2.201 billion yuan, with a net amount of 2.109 billion yuan after deducting issuance costs [1] - The final net amount raised exceeded the original plan by 907 million yuan [1] Group 2: Fund Allocation - The funds raised are intended for the company's headquarters and new R&D base project, expansion of the marketing network, and to supplement working capital [1] - The total issuance costs for the IPO were 91.38 million yuan, with Huatai United Securities receiving 72.64 million yuan as underwriting and sponsorship fees [1] Group 3: Strategic Investment - Huatai Innovation Investment Co., a subsidiary of the sponsoring institution, participated in the strategic placement of the IPO, acquiring 120.03 thousand shares, which is 3% of the total issuance [1] - The lock-up period for the shares acquired by Huatai Innovation is set for 24 months, starting from the date of listing on the Shanghai Stock Exchange [1]

Core Points - The stock price of NuoVivian increased by 2.10% on October 15, reaching 22.82 CNY per share, with a total market capitalization of 9.076 billion CNY [1] - The company has seen a year-to-date stock price increase of 3.63%, but has experienced a decline of 1.68% over the last five trading days [1] - NuoVivian's main business involves the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents and 9.99% from diagnostic reagents [1] Financial Performance - As of June 30, NuoVivian had 8,596 shareholders, an increase of 2.37% from the previous period, while the average circulating shares per person decreased by 2.31% to 46,269 shares [2] - For the first half of 2025, NuoVivian reported a revenue of 606 million CNY, a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.1294 million CNY, down 80.63% year-on-year [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million CNY in dividends, with 611 million CNY distributed over the past three years [3]

Company Overview - NuoVance Biotechnology Co., Ltd. is located in Nanjing Economic and Technological Development Zone, Jiangsu Province, and was established on March 16, 2012. The company went public on November 15, 2021. Its main business involves the research and development of functional proteins and high molecular organic materials, focusing on enzymes, antigens, and antibodies [1][2]. Financial Performance - For the first half of 2025, NuoVance reported operating revenue of 606 million yuan, a year-on-year decrease of 6.63%. The net profit attributable to shareholders was 3.1294 million yuan, down 80.63% year-on-year [2]. - Since its A-share listing, NuoVance has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3]. Stock Performance - As of October 14, NuoVance's stock price increased by 2.00% to 22.92 yuan per share, with a trading volume of 21.1964 million yuan and a turnover rate of 0.24%. The total market capitalization is 9.116 billion yuan [1]. - Year-to-date, the stock price has risen by 4.09%, but it has seen declines of 0.52% over the last five trading days, 2.76% over the last 20 days, and 1.55% over the last 60 days [1]. Shareholder Information - As of June 30, NuoVance had 8,596 shareholders, an increase of 2.37% from the previous period. The average number of tradable shares per shareholder was 46,269, a decrease of 2.31% [2]. Business Segments - The company's main revenue sources are as follows: biological reagents (81.86%), diagnostic reagents (9.99%), consumables and materials (3.15%), instruments and equipment (2.96%), technical services (1.85%), and others (0.18%) [1].